

Sustainable Global Equity Q2 2025





#### Overview

AptarGroup (Aptar) is a US-based manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.

### At a glance:

# US\$10.4bn

Market capitalisation (May 2025)

**US\$3.6bn** 

Revenue (Financial year 2024)

13,500 Employees (Financial year 2024)

#### **Investment case**

- High-quality business with long track-record for compounding revenue and earnings.
- Experienced management team.
- Robust growth within its pharma business, supported by growth in several product categories.

#### Theory of change

#### 1. Circular packaging

Aptar is a leading global producer of plastic closures, pumps and flow control valves for the pharmaceutical sector, as well as the beauty, beverage and personal goods end markets.

Its products are typically produced from polypropylene (PP) or polyethylene (PE), both of which are derived from fossil fuels. Moreover, such consumer packaging is associated with littering and waste generation.

Aptar is well positioned to support its clients to develop solutions which are more easily recyclable – as well as reusable or produced from recycled materials – which would help to more effectively address the associated environmental challenges.

189,000 MT

CO₂e Scope 1 & 2 GHG emissions (Financial year 2024)

#### 2. Product-use impact

The company's pharma portfolio includes nasal spray pumps, metering valves, ophthalmic systems, elastomeric components for injectable medications, and digital health technologies. In the US, the healthcare sector is responsible for 554 million metric tonnes of carbon dioxide equivalent (CO $_{\rm 2}$ e) emissions annually – approximately 8% of national emissions. A significant proportion of these emissions are caused by medical devices, with metered-dose inhalers (MDIs) a prominent contributor; the carbon footprint of each MDIs is estimated to be about 48kg of CO $_{\rm 2}$ e per inhaler because of hydrofluorocarbon propellants.

Aptar is a leading global supplier of inhaler components, including for pressurised Metered Dose Inhalers (pMDIs) – its metering valve is widely used in commercial asthma products. It is estimated that there are more than 800 million inhalers produced globally each year.<sup>3</sup> Aptar is well positioned to support industry product innovation in order to develop and introduce lower-Global Warming Potential (GWP) propellant technologies.

#### 3. Decent work

Aptar employs more than 13,000 people across western Europe and the US, as well as other regions. The company's employment practices provide it with the capability to provide 'decent work'<sup>4</sup> for its staff – which should help safeguard and enhance employees' physical, mental and financial wellbeing.

#### **Practice of change**

Federated Hermes has been invested in, and engaged with, Aptar for more than 20 years. We have had regular meetings with management, and since 2018 we have had more than 25 interactions to discuss the aforementioned topics.


Our engagement with the company encompasses meetings with senior management and site visits, as well as calls and other correspondence. We have always found the company to be receptive to these discussions.

#### 1. Circular packaging

The company has committed to:

- 100% of products being recyclable, reusable or compostable across its Beauty and Closures segment by the end of 2025.
- 10% recycled resin content.

Figure 1: Recyclability of Aptar's products



Source: company reports.

The priority is to now convert the company's main technologies into fully recyclable, single-material solutions, while also increasing the use of recycled resins. As at the end of financial year (FY) 2024 the company has converted approximately 75% of its offerings so that they are either recyclable, reusable or compostable.

Product innovations – such as the company's 'Future' monomaterial pump and its 'SimpliCycle' recyclable valve – should ensure this proportion increases further.



When a 'Future' pump is used with a polyethylene terephthalate (PET) container the recyclability rate moves from low double digits towards 100%.

The company's 'Simplicity' valve has a low density which allows it to float, and is therefore easily separated from the PET waste stream and recycled [with polypropylene (PP) or polyethylene (PE) plastics]. Beyond consumer products, it is also encouraging that the company has also launched the first fully recyclable pharmaceutical nasal spray.

In addition, the industry's conversion to recycled resin continues. It has been hindered by the lack of food-grade post-consumer resin available in the market. We expect this trend to accelerate in the coming years as availability improves.


Aptar ended 2024 with almost 2% of its total resin volume sales using recycled resin content.

In addition to circularity, the company has made significant progress in phasing out 'forever chemicals' – such as PFAS<sup>5</sup> – ahead of future restrictions.

#### 2. Decent work

Over the last few years we have had numerous engagements with the company on matters related to the financial, physical and mental wellbeing of its employees. We have found management to be receptive to these discussions and willing to implement the necessary steps; this can be evidenced in the sharp reduction in accidents at the company and improvement in employee sentiment.

Figure 2: 73% reduction in accidents (2018-24)



Source: company reports.6



Figure 3: Improving employee sentiment



Among the topics we have discussed with the company include career development and training, as well as support for employee mental health and wellbeing and the provision of a living wage.

In terms of career development, the company established Aptar Corporate University in 2018 to help train skilled technicians for manufacturing jobs following a recognition that there was a shortage in the labour market. The investment should help support the company's future operational performance.

Meanwhile, on the issue of paying a living wage, the company has undertaken a living wage gap analysis where it identified modest gaps in its US, Mexican and Brazilian operations. Aptar repeated the exercise earlier this year and noted that the gap has narrowed.

<sup>&</sup>lt;sup>5</sup> PFAS, or per- and polyfluoroalkyl substances, are a group of human-made chemicals that have been used in various industrial and consumer products for their water- and grease-resistant properties. These chemicals are often referred to as 'forever chemicals' because they do not break down easily in the environment and can accumulate over time.

<sup>&</sup>lt;sup>6</sup> Per Glassdoor reviews

#### 3. Product-use impact

We were pleased to see the company was awarded a contract by the US Food and Drug Administration (FDA) in 2023 to study the challenges with developing low-GWP<sup>8</sup> propellants for metered-dose inhalers. It has made significant progress in this area.

Aptar's 'ZEN30 Futurity' metering valve has been designed to support the introduction of the latest low GWP propellant in the next generation of pressurised metered-dose inhalers (pMDIs). The company has played a key role in developing and testing new formulations.

## The introduction of low GWP propellants are expected to reduce inhaler GHG emissions by at least 90%.9

 Leading pharmaceutical group GSK – which is one of Aptar's customers – estimates that the switch in propellant technology will halve its carbon footprint.<sup>10</sup>

#### Other

Aptar established Science-Based Targets in 2018, and updated its targets in 2023. The company's emissions reduction goal is consistent with a 1.5 degree scenario outlined in the Paris Agreement.

Aptar's targets:

- Reduce Scope 1 and 2 emissions by 82% by 2030 (vs. 2019).
- Source 100% of its electricity from renewable sources.
- Reduce Scope 3 absolute emissions by 14% by 2030 (vs. 2019).

At the end of FY 2024, the company had made significant progress towards its first two targets (a 76% reduction in Scope 1 and 2 emissions; 97.5% of its electricity is from renewable sources). However, progress towards its reduction in Scope 3 emissions has been more modest (0.2%).<sup>11</sup>

In addition to Aptar's focus on utilising recycled plastics, the company continues to engage with its resin suppliers (where data quality remains variable). Plastic resin purchases make up almost 75% of Aptar's purchased goods-related emissions (which itself constitutes more than 75% of its total emissions footprint.)

#### **Next steps**

We continue to engage with Aptar on the topics outlined in this report.

Across the pharmaceutical industry, greater consideration is being given to circularity principles<sup>12</sup> and the impact the sector might have on the environment. This shift provides Aptar with a significant opportunity, to continue to develop innovation solutions which:

- Reduce the pharma industry's impact on the environment;
- Enhance revenue opportunities for its business and;
- Deliver lifesaving drug-delivery technologies to customers globally.

This information does not constitute a solicitation or offer to any person to buy or sell any related securities or financial instruments.

<sup>&</sup>lt;sup>8</sup> Global Warming Potential (GWP)

<sup>9</sup> Reducing carbon footprint of inhalers: analysis of climate and clinical implications of different scenarios in five European countries - PMC

<sup>&</sup>lt;sup>10</sup> GSK says new inhaler will help slash its carbon footprint | pharmaphorum

<sup>11</sup> Company reports

<sup>&</sup>lt;sup>12</sup> Circularity principles: There are three core principles to a circular economy. It is based on three principles, driven by design: eliminate waste and pollution, circulate products and materials (at their highest value), and regenerate nature.

The value of investments and income from them may go down as well as up, and you may not get back the original amount invested. Any investments overseas may be affected by currency exchange rates. Past performance is not a reliable indicator of future results and targets are not guaranteed.

For professional investors only. This is a marketing communication. It does not constitute a solicitation or offer to any person to buy or sell any related securities, financial instruments or financial products. No action should be taken or omitted to be taken based on this document. Tax treatment depends on personal circumstances and may change. This document is not advice on legal, taxation or investment matters so investors must rely on their own examination of such matters or seek advice. Before making any investment (new or continuous), please consult a professional and/or investment adviser as to its suitability. Any opinions expressed may change. All figures, unless otherwise indicated, are sourced from Federated Hermes. Whilst Federated Hermes has attempted to ensure the accuracy of the data it is reporting, it makes no representations or warranties, expressed or implied, as to the accuracy or completeness of the information reported. The data contained in this document is for informational purposes only, and should not be relied upon to make investment decisions. Federated Hermes shall not be liable for any loss or damage resulting from the use of any information contained on these pages. All performance includes reinvestment of dividends and other earnings. Please consider all strategy characteristics when investing and not just ESG characteristics. The strategy has environmental and/or social characteristics and so may perform differently to other strategies, as its exposures reflect its sustainability criteria.

Federated Hermes refers to Federated Hermes Limited ("Federated Hermes"). The main entities operating under Federated Hermes are: Hermes Investment Management Limited ("HIML"); Hermes Fund Managers Ireland Limited ("HFMIL"); Hermes Alternative Investment Management Limited ("HREIML"); Hermes Equity Ownership Services Limited ("EOS"); Hermes Stewardship North America Inc. ("HSNA"); Hermes GPE LLP ("Hermes GPE"); Hermes GPE (USA) Inc. ("Hermes GPE USA"); Hermes GPE (Singapore) Pte. Ltd ("HGPE Singapore"); Federated Investors Australia Services Pty Ltd. ("FIAS"); Federated Hermes Japan Ltd ("FHJL"); Federated Hermes (UK) LLP ("FHUK") and Rivington Energy (Management) Limited ("REML"). FHL is the majority shareholder in REML. FHUK, HIML, HAIML and Hermes GPE are each authorised and regulated by the Financial Conduct Authority. HAIML and HIML carry out regulated activities associated with HREIML. FHUK, HIML, Hermes GPE and Hermes GPE USA are each a registered investment adviser with the United States Securities and Exchange Commission ("SEC") and HAIML and HFMIL are each an exempt reporting adviser. HGPE Singapore is regulated by the Monetary Authority of Singapore. FHJL is regulated by Japan Financial Services Agency. FIAS holds an Australian Financial Services Licence. HFMIL is authorised and regulated by the Central Bank of Ireland. REML, HREIML, EOS and HSNA are unregulated and on not engage in regulated activity.

In the European Economic Area ("EAA") this document is distributed by HFMIL. Contracts with potential investors based in the EEA for a segregated account will be contracted with HFMIL.

Issued and approved by Hermes Investment Management Limited which is authorised and regulated by the Financial Conduct Authority. Registered address: Sixth Floor, 150 Cheapside, London EC2V 6ET. Telephone calls may be recorded for training and monitoring purposes. Potential investors in the United Kingdom are advised that compensation may not be available under the United Kingdom Financial Services Compensation Scheme.

In Argentina: These materials and the information contained herein does not constitute and is not intended to constitute an offer and accordingly should not be construed as such. The products or services referenced in these materials may not be licensed in all jurisdictions, and unless otherwise indicated, no regulator or government authority has reviewed these materials, or the merits of the products and services referenced herein. These materials and the information contained herein has been made available in accordance with the restrictions and/or limitations implemented by any applicable laws and regulations. These materials are directed at and intended for institutional investors (as such term is defined in each jurisdiction in which these materials are being marketed). These materials are provided on a confidential basis for informational purposes only and may not be reproduced in any form. Before acting on any information in these materials, prospective investors should inform themselves of and observe all applicable laws, rules and regulations of any relevant jurisdictions and obtain independent advice if required. These materials are for the use of the named addressee only and should not be given, forwarded or shown to any other person (other than employees, agents or consultants in connection with the addressee's consideration thereof).

In Australia: This Strategy Document relates to potential offer of financial products or investment opportunities in Australia (Investment opportunities). Both Hermes Investment Management Ltd (HIML) and Federated Investors Australia Services Ltd. ACN 161 230 637 (FIAS) are the distributors of the Investment opportunities. HIML does not hold an Australian financial services licence (AFS licence) under the Corporations Act 2001 (Cth) ("Corporations Act"). HIML operates under the relevant class order relief from the Australian Securities and Investments Commission (ASIC) while FIAS holds an AFS licence (Licence Number - 433831).

The offer of Investment opportunities only made in circumstances under which no disclosure is required under Chapter 6D and Part 7.9 of the Corporations Act. Nothing in this Strategy Document is, or purports to be, an offer to a person to whom disclosure would be required under Chapter 6D or Part 7.9 of the Corporations Act.

This Strategy Document is not a disclosure document under Chapter 6D of the Corporations Act or a product disclosure statement for the purposes of Part 7.9 of the Corporations Act. This Strategy Document has not been and will not be lodged with ASIC and does not contain all the information that a disclosure document or a product disclosure statement is required to contain. The distribution of this Strategy Document in Australia has not been authorised by ASIC or any other regulatory authority in Australia. In addition, the Fund is not a registered managed investment scheme, as defined in the Corporations Act.

This Strategy Document is provided for general information purposes only and is not intended to constitute, and does not constitute, the provision of any financial product advice or recommendation and must not be relied upon as such. This Strategy Document is not intended to influence a person in making a decision in relation to a particular financial product or class of financial products, or an interest in a particular financial product or class of financial products.

This Strategy Document has been prepared without taking account of your objectives, financial situation or needs and you should obtain independent professional financial advice that considers your circumstances before making any financial or investment decisions.

**In Bahrain:** This document has not been approved by the Central Bank of Bahrain which takes no responsibility for its contents. No offer to the public to purchase the strategies will be made in the Kingdom of Bahrain and this document is intended to be read by the addressee only and must not be passed to, issued to, or shown to the public generally.

**In Brazil:** The strategies may not be offered or sold to the public in Brazil. Accordingly, the strategies have not been nor will be registered with the Brazilian Securities Commission - CVM nor have they been submitted to the foregoing agency for approval. Documents relating to the strategies, as well as the information contained therein, may not be supplied to the public in Brazil, as the offering of strategies is not a public offering of securities in Brazil, nor used in connection with any offer for subscription or sale of securities to the public in Brazil.

**In Brunei:** This document is intended for distribution only to specific classes of investors as specified in the Order and must not, therefore, be delivered to, or relied on by, a retail client. The Autoriti Monetari Brunei Darussalam is not responsible for reviewing any documents in connection with these strategies. Prospective purchasers of the strategy should conduct their own due diligence.

**In Chile:** Federated Hermes is not registered or licensed in Chile to provide managed account services and is not subject to the supervision of the Comisión para el Mercado Financiero of Chile ("CMF"). The managed account services may not be publicly offered or sold in Chile.

In China: This document does not constitute a public offer of the strategies in the People's Republic of China (the "PRC"). The strategies are not being offered or sold directly or indirectly in the PRC to or for the benefit of, legal or natural persons of the PRC. Further, no legal or natural persons of the PRC may directly or indirectly purchase any of the strategies or any beneficial interest therein without obtaining all prior PRC's governmental approvals that are required, whether statutorily or otherwise. Persons who come into possession of this document are required by the issuer and its representatives to observe these restrictions.

In Colombia: This document does not have the purpose or the effect of initiating, directly or indirectly, the purchase of a product or the rendering of a service by Federated Hermes ("investment adviser") to Colombian residents. The investment adviser's products and/or services may not be promoted or marketed in Colombia or to Colombian residents unless such promotion and marketing is made in compliance with decree 2555 of 2010 and other applicable rules and regulations related to the promotion of foreign financial and/or securities related products or services in Colombia. The investment adviser has not received authorisation of licensing from the Financial Superintendency of Colombia or any other governmental authority in Colombia to market or sell its financial products or services in Colombia. By receiving this document, each recipient resident in Colombia acknowledges and agrees that such recipient has contacted the investment adviser at its own initiative and not as a result of any promotion or publicity by the investment adviser or any of its representatives. Colombian residents acknowledge and represent that (1) the receipt of this presentation does not constitute a solicitation from the investment adviser for its financial products and/or services, and (2) they are not receiving from the investment adviser any direct or indirect promotion or marketing of financial products and/or services.

In Hong Kong: The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of this document, you should obtain independent professional advice. The strategies are not authorised under Section 104 of the Securities and Futures Ordinance of Hong Kong by the Securities and Futures Commission of Hong Kong. Accordingly, the distribution of this document, and the placement of interests in Hong Kong, is restricted. This document may only be distributed, circulated or issued to persons who are professional investors under the Securities and Futures Ordinance and any rules made under that Ordinance or as otherwise permitted by the Securities and Futures Ordinance.

In Israel: This document has not been approved by the Israel Securities Authority and will only be distributed to Israeli residents in a manner that will not constitute "an offer to the public" under sections 15 and 15a of the Israel Securities Law, 5728-1968 ("the Securities Law") or section 25 of the Joint Investment Trusts Law, 5754-1994 ("the Joint Investment Trusts Law"), as applicable. The strategies are being offered to a limited number of investors (35 investors or fewer during any given 12 month period) and/or those categories of investors listed in the First Addendum ("the Addendum") to the Securities Law, ("Sophisticated Investors") namely joint investment funds or mutual trust funds, provident funds, insurance companies, banking corporations (purchasing strategies for themselves or for clients who are Sophisticated Investors), portfolio managers (purchasing strategies for themselves or for clients who are Sophisticated Investors), investment advisors or investment marketers (purchasing strategies for themselves), members of the Tel-Aviv Stock Exchange (purchasing strategies for themselves or for clients who are Sophisticated Investors), underwriters (purchasing strategies for themselves), venture capital funds engaging mainly in the capital market, an entity which is wholly-owned by Sophisticated Investors, corporations, (other than formed for the specific purpose of an acquisition pursuant to an offer), with a shareholder's equity in excess of NIS 50 million, and individuals in respect of whom the terms of item 9 in the Schedule to the Investment Advice Law hold true investing for their own account, each as defined in the said Addendum, as amended from time to time, and who in each case have provided written confirmation that they qualify as Sophisticated Investors, and that they are aware of the consequences of such designation and agree thereto; in all cases under circumstances that will fall within the private placement or other exemptions of the Joint Investment Trusts Law, the Securities Law and any applicable guidelines, pronouncements or rulings issued from time to time by the Israel Securities Authority. This document may not be reproduced or used for any other purpose, nor be furnished to any other person other than those to whom copies have been sent. Any offeree who purchases strategies is purchasing such strategies for its own benefit and account and not with the aim or intention of distributing or offering such strategies to other parties (other than, in the case of an offeree which is a Sophisticated Investor by virtue of it being a banking corporation, portfolio manager or member of the Tel-Aviv Stock Exchange, as defined in the Addendum, where such offeree is purchasing strategies for another party which is a Sophisticated Investor). Nothing in this document should be considered investment advice or investment marketing as defined in the Regulation of Investment Counselling, Investment Marketing and Portfolio Management Law, 5755-1995. Investors are encouraged to seek competent investment counselling from a locally licensed investment counsel prior to making the investment. As a prerequisite to the receipt of a copy of this document a recipient may be required by the Issuer to provide confirmation that it is a Sophisticated Investor purchasing strategies for its own account or, where applicable, for other Sophisticated Investors. This document does not constitute an offer to sell or solicitation of an offer to buy any securities other than the strategies offered hereby, nor does it constitute an offer to sell to or solicitation of an offer to buy from any person or persons in any state or other jurisdiction in which such offer or solicitation would be unlawful, or in which the person making such offer or solicitation is not qualified to do so, or to a person or persons to whom it is unlawful to make such offer or solicitation.

In Japan: Federated Hermes Japan Ltd is registered as a Financial Instruments Business Operator in Japan (Registration Number: Director General of the Kanto Local Finance Bureau (Kinsho) No. 3327), and conducting the Investment Advisory and Agency Business as defined in Article 28 (3) of the Financial Instruments and Exchange Act (FIEA). Federated Hermes Japan Ltd is acting as agent or intermediary for the conclusion of investment advisory contracts or discretionary investment contracts between affiliated companies within the Federated Hermes group and Japanese licensed discretionary investment managers, trust banks and other Japanese financial institutions. Federated Hermes Japan Ltd is a member of Japan Investment Advisers Association (JIAA). Reference to Federated Hermes in this material is not limited to Federated Hermes Japan Ltd, but includes group affiliates.

**In Kuwait:** This document is not for general circulation to the public in Kuwait. The strategies have not been licensed for offering in Kuwait by the Kuwait Capital Markets Authority or any other relevant Kuwaiti government agency. The offering of the strategies in Kuwait on the basis of a private placement or public offering is, therefore, restricted in accordance with Law No. 7 of 2010 and the bylaws thereto (as amended). No private or public offering of the strategies is being made in Kuwait, and no agreement relating to the sale of the strategies will be concluded in Kuwait. No marketing or solicitation or inducement activities are being used to offer or market the strategies in Kuwait.

In The Sultanate of Oman: The information contained in this document neither constitutes a public offer of securities in the Sultanate of Oman as contemplated by the Commercial Companies Law of Oman (Royal Decree 4/74) or the Capital Market Law of Oman (Royal Decree 80/98), nor does it constitute an offer to sell, or the solicitation of any offer to buy Non-Omani securities in the Sultanate of Oman as contemplated by Article 139 of the Executive Regulations to the Capital Market Law (issued by Decision No.1/2009). Additionally, this document is not intended to lead to the conclusion of any contract of whatsoever nature within the territory of the Sultanate of Oman.

**In Peru:** All content in this presentation is for information or general use only. The information contained in this presentation is referential and may not be construed as an offer, invitation or recommendation, nor should be taken as a basis to take (or stop taking) any decision. This presentation has been prepared on the basis of public information that is subject to change. This information may not be construed as services provided by Federated Hermes, Inc. within Peru without having the corresponding banking or similar license according to the applicable regulation.

In Saudi Arabia: The document is provided at your request. This document is only available to (i) Authorised Persons, (ii) Exempt Persons or (iii) institutions. The strategy is not registered in Saudi Arabia

**In South Africa:** This document is not intended and does not constitute an offer, invitation, or solicitation by any person to members of the public to invest. This document is not an offer in terms of Chapter 4 of the Companies Act, 2008. Accordingly this document does not, nor is it intended to, constitute a prospectus prepared and registered under the Companies Act.

In South Korea: Hermes Investment Management Limited is not making any representation with respect to the eligibility of any recipients of this document to acquire the strategies therein under the laws of Korea, including but without limitation the Foreign Exchange Transaction Act and Regulations thereunder. The strategies have not been registered under the Financial Investment Services and Capital Markets Act of Korea, and none of the strategies may be offered, sold or delivered, or offered or sold to any person for re-offering or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to applicable laws and regulations of Korea.

**In Spain:** This document is issued by Hermes Fund Managers Ireland Limited, Branch in Spain, with Fiscal Identity Number W0074815B, registered in the Mercantile Registry of Madrid, - Volume 40448, Book 0, Sheet 16, Section 8, Page M-718259, first registration, with domicile at Paseo de la Castellana 18, 5° planta, 28046 Madrid - Spain, and registered in the Comisión Nacional del Mercado de Valores with official registration number 36.

**In Thailand:** The document has not been approved by the Securities and Exchange Commission which takes no responsibility for its contents. No offer to the public to purchase the strategies will be made in Thailand and this document is intended to be read by the addressee only and must not be passed to, issued to, or shown to the public generally.

In United Arab Emirates (Excluding Dubai International Financial Centre and Abu Dhabi Global Market): This document, and the information contained herein, does not constitute, and is not intended to constitute, a public offer of securities in the United Arab Emirates and accordingly should not be construed as such. The strategies are only being offered to a limited number of sophisticated investors in the UAE who (a) are willing and able to conduct an independent investigation of the risks involved in an investment in such strategies, and (b) upon their specific request. The strategies have not been approved by or licensed or registered with the UAE Central Bank, the Securities and Commodities Authority or any other relevant licensing authorities or governmental agencies in the UAE. The document is for the use of the named addressee only and should not be given or shown to any other person (other than employees, agents or consultants in connection with the addressee's consideration thereof). No transaction will be concluded in the UAE and any enquiries regarding the strategies should be made to Hermes Investment Management Limited in London.

In Uruguay: These materials and the information contained herein does not constitute and is not intended to constitute an offer and accordingly should not be construed as such. The products or services referenced in these materials may not be licensed in all jurisdictions, and unless otherwise indicated, no regulator or government authority has reviewed these materials, or the merits of the products and services referenced herein. These materials and the information contained herein has been made available in accordance with the restrictions and/or limitations implemented by any applicable laws and regulations. These materials are directed at and intended for institutional investors (as such term is defined in each jurisdiction in which these materials are being marketed). These materials are provided on a confidential basis for informational purposes only and may not be reproduced in any form. Before acting on any information in these materials, prospective investors should inform themselves of and observe all applicable laws, rules and regulations of any relevant jurisdictions and obtain independent advice if required. These materials are for the use of the named addressee only and should not be given, forwarded or shown to any other person (other than employees, agents or consultants in connection with the addressee's consideration thereof).



#### **Federated Hermes**

Federated Hermes is a global leader in active, responsible investing.

Guided by our conviction that responsible investing is the best way to create long-term wealth, we provide specialised capabilities across equity, fixed income and private markets, multi-asset and liquidity management strategies, and world-leading stewardship.

Our goals are to help people invest and retire better, to help clients achieve better risk-adjusted returns and, where possible, to contribute to positive outcomes that benefit the wider world.

# Our investment and stewardship capabilities:

- Active equities: global and regional
- Fixed income: across regions, sectors and the yield curve
- Liquidity: solutions driven by five decades of experience
- Private markets: private equity, private credit, real estate and infrastructure
- Stewardship: corporate engagement, proxy voting and policy advocacy

For more information, visit **www.hermes-investment.com** or connect with us on social media:



